Replies to post #32351 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Medivation still claims to believe that they can file on the basis of this about-to-complete trial plus the Russian results. Right.

The $225 million in upfront money is less impressive when you consider that they have to cover 40% of the Phase III trial costs.

NeuroInvestment